Skin Biology & Research

Microcrack Coating Kills 80% of Bacteria With One 9-Volt Pulse

Microscopic cracks turn flexible coatings into electrically activated bacteria killers
malucero / pixabay

A flexible gallium–carbon nanotube coating killed more than 80% of bacterial cells within three hours after just one minute of stimulation from a standard 9-volt battery, Flinders University researchers reported November 12, 2026 in the journal Small Structures.

The study tested the material against methicillin-resistant Staphylococcus aureus (MRSA), a leading cause of hard-to-treat hospital infections, and Pseudomonas aeruginosa, which triggers serious infections in vulnerable patients. Lab testing showed the coating remained compatible with human skin cells under the conditions tested.

Why cracks make it work

The breakthrough inverts a core engineering assumption: cracks are defects to be prevented. Here, researchers deliberately harnessed them.

The team built the coating from liquid gallium — a metal that melts near room temperature — combined with carbon nanotubes. As the film dried, networks of microscopic cracks formed naturally across the surface. Rather than weakening the material, those cracks created tiny electrical hotspots that appeared to amplify its bacteria-killing power.

"Most engineers spend a great deal of time trying to prevent cracks from forming, but we've shown that when they are carefully controlled, these tiny cracks can actually create new opportunities," said Associate Professor Vi-Khanh Truong of Flinders University's College of Medicine and Public Health and the Flinders Health and Medical Research Institute (FHMRI).

"Instead of seeing cracks as defects, we've demonstrated they can be designed into materials to create useful functions," Truong said.

What kills the bacteria?

The mechanism appears to be twofold.

Electrical stimulation increased stress inside bacterial cells, helping damage and destroy them. The coating could also generate plasma — an energised gas that produces reactive molecules known to suppress bacterial growth.

The antimicrobial response is switchable. "Our approach combines smart material design with electrical stimulation to create an antimicrobial response that can be switched on when needed," Truong said.

Why it matters for wound care

The findings land as antibiotic resistance is recognised as one of the world's most pressing health threats. Truong said technologies that prevent or control infections without relying solely on antibiotics are becoming increasingly important.

"Antibiotic-resistant infections are one of the major healthcare challenges facing the world, so there is growing interest in finding new ways to prevent infections before they become established," he said.

For dermatology and wound care, the near-term target is clear: flexible medical devices that treat infection directly at the source, including wounds that are difficult to heal. The material bends, stretches and conducts electricity, so the researchers envision soft skin patches or smart textiles that monitor health signals such as heart or muscle activity while simultaneously preventing infection.

How far from the clinic?

The technology is still at an early stage, and the researchers did not claim a timeline for human use. The published data cover in vitro bacterial killing and skin-cell compatibility, not animal or clinical trials.

Still, Truong framed the result as proof that a long-dismissed flaw can become a function. "There's still more work to do before this reaches patients, but these results show it's possible to turn something traditionally considered a flaw into a flexible, conductive material that actively fights infection," he said.

If the hotspots hold up in vivo, stress-programmed microcrack films could give clinicians a dressing that monitors a wound and sterilises it on demand — no antibiotics required.

Source: nanowerk.com

Share this article:

Tom Whitfield

Show full bio

Senior reporter covering companies, deals and strategy in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Tom Whitfield →

Related articles

« Previous articleNext article »